Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial-Reference-Cited by-同舟云学术

Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial

Published:1980-12-15 Issue:S12 Volume:46 Page:2805-2808
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hubay Charles A.,Pearson Olof H.,Marshall James S.,Rhodes Robert S.,Debanne Sara M.,Rosenblatt Judah,Mansour Edward G.,Hermann Robert E.,Jones James C.,Flynn William J.,Eckert Charles,McGuire William L,

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference10 articles.

1. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy

2. The Relation between Estrogen Receptors and Response Rate to Cytotoxic Chemotherapy in Metastatic Breast Cancer

3. Estrogen Receptors and Responses to Chemotherapy and Hormonal Therapy in Advanced Breast Cancer

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis;Translational Breast Cancer Research;2022-01

2. Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial;Acta Oncologica;2017-11-22

3. Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?;Expert Review of Anticancer Therapy;2017-03-10

4. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer;Endocrine-Related Cancer;2014-03-21

5. Hormonrezeptoranalyse und Zytostatika-Sensitivitätstestung: Stellenwert in der Zusatztherapieplanung des Mammakarzinoms;DMW - Deutsche Medizinische Wochenschrift;2008-03-26